The World Health Organization estim...

The World Health Organization estimates that more than 25 million deaths worldwide can be attributed to obesity each year, and the number continues to increase. not many safe and effective medications are available for obesity, moreover new understanding of the physiologic regulation of feed intake and calorie storage have l to the evolution of therapies targeting the endocannabinoid order This system is overactive in animal designs of obesity and is believed to modulate meat intake and adipogenesis through receptors (C[Bsub1]) in the brain and a variety of peripheral tissues. Van Gaal and colleagues studied a CB1-blocking mix with drugs rimonabant (Acomplia), in a large trial of adult obese patients.

The researchers recruited more than 1500 obese adults from 60 European and U center Inclusion criteria were a corpse mass index (BMI) of 30 or a BMI of 27 plus hypertension or dyslipidemia. Participants also were required to have experienced les than 11-lb (5-kg) variation in carcass weight in the three month before the thought and to be free from significant cardiovascular, pulmonary, hepatic, renal, neurologic, psychiatric, and endocrine disease, including diabetes. Participants were exclud if they had a history of surgical deeds for weight loss or of significant depression, were generally taking medications known to influence carcass weight, or intended to change their smoking status during the thought period.

After extensive baseline assessment, including basal metabolic rate, material part measurements, glucose tolerance testing, and other laboratory screening, 1507 participants were randomly assigned to 5 mg by day of rimonabant, 20 mg by day of rimonabant, or placebo. All patients were advised in succession diet and exercise based forward their personal basal metabolic rate. Patients were reassessed each 14 days for one month then each 28 days for two years.

Patients in the three arranges were comparable in all significant variables at baseline. no other than 61 percent of participants complet the one-year follow-up: 379 (627 percent) in the 5-mg assign places to 363 (60.6 percent) in the 20-mg arrange and 178 (58.4 percent) in the placebo form into groups Using intention-to-treat analysis, researchers rest that patients taking rimonabant had significantly greater weight los and improvement in lipids and insulin function after common year than those taking placebo. This general intent was more pronounced if the analysis was limited to participants who complet single year of assigned therapy. In this analysis, the cumulative weight los was 11 lb (5 kg) in the placebo clump compared with more than 22 lb (10 kg) in the 20-mg dispose The percentage of patients with 10 percent or more weight los was significantly greater in the 20-mg form into groups (27.4 percent) than the placebo collection (7.3 percent) but not in the 5-mg assemblage (10.1 percent). If only those patients who complet the thought were considered, these figures rose to 39 percent in the 20-mg arrange 12.4 percent in the placebo cluster and 15.3 percent in the 5-mg cluster Waist circumference and lipid profile also improved significantly in patients taking rimonabant. The proportion of patients with metabolic syndrome decreased from 412 to 286 percent in those taking 5 mg and from 422 to 196 percent in those taking 20 mg compared with a decrease from 399 to 314 percent in the placebo cluster In about one half of participants, improvement in metabolic risk factors was independent of weight los Adverse efficiencys were reported by more than 80 percent of patients in all three assign places tos but most were mild and transitory. The greatest number of discontinuations (87) occurr in the 20-mg form into groups with almost one half (42) being attributed to psychiatric disturbance.

The authors decide that rimonabant in conjunction with diet and exercise issueed in significant weight loss plus reduction in metabolic risk factors. Although understanding of the endocannabinoid a whole is incomplete, the system appears to play a significant part in food intake and strength homeostasis. Medications blocking receptors in this rule have the potential to contribute significantly to antiobesity therapy.

ANNE D WALLING, MD Van Gaal LF et al. weights of the cannabinoid-1 receptor blocker rimonabant in succession weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe contemplation Lancet April 16, 2005;365:1389-97.

EDITOR'S NOTE: sum of two units interesting observations from this contemplation are the lack of power of weight loss on offspring pressure and the performance of the placebo dispose The 178 patients who complet united year taking placebo experienced a mean weight los of 9 lb (4 kg) plus a least bit in triglycerides and a rise in high-density lipoprotein cholesterol Although these are virtuous gains, they confirm that support, advice about exercise and diet, and patient confidence can be of benefit in this intractable condition. For those who remain wary of medications for weight los the consideration offers validation of the old-fashioned advice about lifestyle as well as the expectancy that new therapies might be available in the future.--A.D.W.

COPYRIGHT 2005 American Academy of Family Physicians

COPYRIGHT 2006 Gale Group